Spectris plc has successfully finalized the acquisition of 100% of the share capital of the target from a mid-market private equity firm. This strategic transaction represents a definitive step in the group’s evolution toward a combined product-and-service proposition within its specialized materials analysis segment. The strategic rationale for the move centers on the high degree of complementarity between the target’s scientific service capabilities and the acquirer’s established instrumentation expertise, particularly through its existing subsidiary, Malvern Panalytical. By incorporating this technical specialist, the organization reinforces its ability to serve mission-critical pharmaceutical and agrochemical markets facing increased regulatory complexity. The partnership is designed to leverage the acquirer’s global reach and deep domain knowledge to accelerate innovation in molecular testing and therapy development. This integration facilitates a unique end-to-end offering, providing the strategic depth required to navigate the sophisticated requirements of protein-based pharmaceutical research. The move marks a significant expansion into high-growth life sciences services, positioning the combined entity as a primary enabler of advanced drug discovery workflows.

CONCEPT LIFE SCIENCES, which reported an EBITDA margin of LOGIN in 2017, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.4x average currently observed in the Healthcare & Pharma sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.